Friday, July 10, 2026
🇺🇸 FDA

pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis

PARItec

Pari Pharma GmbH

PARItec clinical programs — 139 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
Status
Public
HQ
Starnberg, DE
Employees
28
Programs
248
Drugs
362
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

PARItec projects

139 ClinicalTrials.gov programs sponsored by PARItec.

PARItec has 139 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

139 programs

Clinical programs

Page 3 of 3

  1. DAPAGLIFLOZIN, PLACEBO DE DAPAGLIFLOZIN 10 mg

    Pari Pharma GmbH

    Cardiac failure

    phase 3 small molecule active

    1 trial

  2. DEXAMETHASONE for Onco-hematology

    Pari Pharma GmbH

    Onco-hematology

    phase 3 small molecule active

    1 trial

  3. DEXMEDETOMIDINE , 18F-DPA-714

    Pari Pharma GmbH

    Patients who survive a COVID ARDS in intensive care must be weaned off invasive mechanical ventilation as quickly as possible. 60% of these patients present with intensive care delirium, a serious event that causes excess mortality and potential acute and late complications, since 30% of patients who present with delirium develop cognitive sequelae. Severe neuroinflammation is considered to be one of the main pathophysiological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine has neuroprotective effects. In certain experimental models, it reduces cerebral inflammation by acting directly on the microglial phenotype. The role of this chronic neuroinflammatory state on cognitive capacity and reserve is beginning to emerge in the literature, regardless of the initial stress (surgery, head injury or Alzheimer's-type dementia), and is therefore capable of influencing patients' quality of life. The assessment of this neuroinflammation using non-invasive tools would appear to be of prime importance in the management of post-COVID neuro injured patients, as well as the evaluation of potential neuroprotective agents such as dexmedetomidine.

    phase 3 small molecule active

    1 trial

  4. ECULIZUMAB , ECULIZUMAB

    Pari Pharma GmbH

    Adult patients with aHUS associated with HE and severe kidney involvement (needing dialysis or serum creatinine ≥ 354μM)

    phase 3 small molecule active

    1 trial

  5. ENOXAPARIN

    Pari Pharma GmbH

    Allograft vascular thrombosis

    phase 3 small molecule active

    1 trial

  6. ETOPOSIDE

    Pari Pharma GmbH

    Hemophagocytic lymphohistiocytosis (HLH)

    phase 3 small molecule active

    1 trial

  7. ETOPOSIDE , DEXAMETHASONE

    Pari Pharma GmbH

    Hemophagocytic lymphohistiocytosis (HLH)

    phase 3 small molecule active

    1 trial

  8. FAMPRIDINE, Placebo 515

    Pari Pharma GmbH

    Spinocerebellar ataxia

    phase 3 small molecule active

    1 trial

  9. FLECAINIDE

    Pari Pharma GmbH

    Patent Foramen Ovale Closure Atrial Arrhytmia or Tachycardia

    phase 3 small molecule active

    1 trial

  10. IRINOTECAN for Middle or low locally advanced resectable rectal carcinoma

    Pari Pharma GmbH

    Middle or low locally advanced resectable rectal carcinoma

    phase 3 small molecule active

    1 trial

  11. Kineret / solution for Familial Mediterranean Fever (F…

    Pari Pharma GmbH

    Familial Mediterranean Fever (FMF)

    phase 3 small molecule active

    1 trial

  12. METFORMIN

    Pari Pharma GmbH

    Type 2 Diabetes complete remission after bariatric surgery under antidiabetic drug

    phase 3 small molecule active

    1 trial

  13. METHOTREXATE for Immune system disorders

    Pari Pharma GmbH

    Immune system disorders

    phase 3 small molecule active

    1 trial

  14. Metalyse 5 000 units (25 mg) powder for solution for injection

    Pari Pharma GmbH

    Adult patients with a LVOS with large core within 9 hours of symptoms onset or last seen well, or with a diffusion weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch in case of unknown onset.

    phase 3 small molecule active

    1 trial

  15. NIFEDIPINE, Placebo of Nifedipine

    Pari Pharma GmbH

    obstetric_pathological delivery

    phase 3 small molecule active

    1 trial

  16. NaCl 0.9%, DEXAMETHASONE

    Pari Pharma GmbH

    Cervicobrachial Neuralgia

    phase 3 small molecule active

    1 trial

  17. OBINUTUZUMAB, RITUXIMAB

    Pari Pharma GmbH

    Idiopathic nephrotic syndrome (INS)

    phase 3 small molecule active

    1 trial

  18. P130937

    Pari Pharma GmbH

    Colorectal adenomas, Lynch syndrome

    phase 3 small molecule active

    1 trial

  19. P140938J

    Pari Pharma GmbH

    Antisynthetase syndrome-related interstitial lung disease

    phase 3 small molecule active

    1 trial

  20. P150952J

    Pari Pharma GmbH

    Smokers smoking at least 10 cigarettes/day in the past year

    phase 3 small molecule active

    1 trial

  21. P150957

    Pari Pharma GmbH

    External Genital Warts (EGW)

    phase 3 small molecule active

    1 trial

  22. P160913

    Pari Pharma GmbH

    Adults patients with isolated acute urticaria presenting to the emergency department

    phase 3 small molecule active

    1 trial

  23. P160924

    Pari Pharma GmbH

    intermediate-high-risk acute pulmonary embolism

    phase 3 small molecule active

    1 trial

  24. P160925J

    Pari Pharma GmbH

    Septic shock

    phase 3 small molecule active

    1 trial

  25. P160931J

    Pari Pharma GmbH

    Adult patients with ulcerative colitis diagnosed for at least 3 months

    phase 3 small molecule active

    1 trial

  26. P170912J

    Pari Pharma GmbH

    Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery)

    phase 3 small molecule active

    1 trial

  27. P170913J

    Pari Pharma GmbH

    PANCREATIC FISTULA

    phase 3 small molecule active

    1 trial

  28. P170916J

    Pari Pharma GmbH

    Intrahepatic non-cirrhotic portal hypertension

    phase 3 small molecule active

    1 trial

  29. P170923J

    Pari Pharma GmbH

    gender dysphoria

    phase 3 small molecule active

    1 trial

  30. P170938J

    Pari Pharma GmbH

    Asplenia

    phase 3 small molecule active

    1 trial

  31. PEGASPARGASE

    Pari Pharma GmbH

    This is a prospective, French, multicenter, open-label, design, stratified on the immunophenotypic characterization (B- or T- lineage) and the patient risk group, that aims at evaluating the efficacy and the tolerance of different schedules of pegaspargase in patients from 12 months to less than 18 years newly diagnosed with standard/medium-risk ALL

    phase 3 small molecule active

    1 trial

  32. PROPRANOLOL

    Pari Pharma GmbH

    Von Hippel-Lindau (VHL) disease

    phase 3 small molecule active

    1 trial

  33. Revatio 0.8 mg/ml solution for injection

    Pari Pharma GmbH

    Hypoxic ischemic encephalopathy

    phase 3 small molecule active

    1 trial

  34. SARCLISA for Patients aged 18-65 years old w…

    Pari Pharma GmbH

    Patients aged 18-65 years old with newly diagnosed previously untreated ALL or T-LL.

    phase 3 small molecule active

    1 trial

  35. SODIUM CHLORIDE, ROPIVACAINE

    Pari Pharma GmbH

    Cancer surgery

    phase 3 small molecule active

    1 trial

  36. SODIUM for Adult cardiac arrest patients w…

    Pari Pharma GmbH

    Adult cardiac arrest patients with sustained ROSC and hemodynamic failure due to post-resuscitation syndrome

    phase 3 small molecule active

    1 trial

  37. Solution de chlorure de sodium à 0 for Adult Patients kidney transplan…

    Pari Pharma GmbH

    Adult Patients kidney transplant recipients who have developed chronic humoral rejection, diagnosed through a kidney biopsy (Banff 2017 Classification), resistant to conventional treatment (3 injections at one-month intervals of 2g/kg of IVIG)

    phase 3 small molecule active

    1 trial

  38. TOCILIZUMAB, Placebo of Tocilizumab

    Pari Pharma GmbH

    Giant cell arteritis with Cerebro-vascular involvement

    phase 3 small molecule active

    1 trial

  39. VISIPAQUE d’I/mL for Knee OsteoArthritis

    Pari Pharma GmbH

    Knee OsteoArthritis

    phase 3 small molecule active

    1 trial

  40. [18F]MNI-659

    Pari Pharma GmbH

    Patients with symptomatic and pre-symptomatic Huntington's disease

    phase 3 small molecule active

    1 trial

  41. [68Ga]Ga-PentixaFor

    Pari Pharma GmbH

    Primary aldosteronism, Primary aldosteronism

    phase 3 small molecule active

    1 trial

  42. cisplatin

    Pari Pharma GmbH

    Lung Cancer

    phase 3 small molecule completed

    1 trial

  43. cpFT

    Pari Pharma GmbH

    Infertility

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does PARItec have?

139 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.